Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

162 results about "Prophylactic treatment" patented technology

A prophylactic treatment is a medical treatment used to prevent the appearance of a disease or other medical problem in a patient who is healthy at the time of treatment.

Substituted oxadiazole-aniline compound and application thereof

The invention belongs to the technical field of medicines, and discloses a substituted oxadiazole-aniline compound, a preparation method thereof, a pharmaceutical composition taking the compound as an active component, and application of the substituted oxadiazole-aniline compound and the pharmaceutical composition in treatment and / or prevention of infectious diseases caused by coronavirus. Specifically, the invention relates to a compound shown as a formula (I) and an isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound disclosed by the invention, and R1, R2, R3, R4 and n are described in the specification. The invention aims to prepare a new compound with anti-coronavirus activity, and the new compound can be used as a potential new drug for treatment or prophylactic treatment of infectious diseases caused by viruses, especially pneumonia diseases caused by coronaviruses. # imgabs0 #
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1

Premature birth prediction

Systems and methods of predicting future medical events are based on the processing of medical images. The prediction of premature birth and estimation of gestational age based on ultrasound images are presented as illustrative examples. The new abilities to estimate the probability of future medical events, before they otherwise could be predicted, provides new avenues for the development of preventative treatments.
Owner:ULTRASOUND AI INC

Seizure forecasting by tracking cortical response to electrical stimulation

PCT designated stage expiredWO2025074081A1Head electrodesSensorsStimulus patternProphylactic treatment
The present disclosure provides a method and system for forecasting the likelihood of seizure onset within an individual. Specifically, the present disclosure relates to an intracranial implant comprising one or more electrodes attached thereto and an associated method for delivering active perturbation patterns to brain regions which includes: sending, via the intracranial implant, an electrical stimuli into a brain, wherein the electrical stimuli is sent in accordance with a stimuli pattern; measuring an output from the brain in response to the electrical stimuli; feeding the output into a forecasting model; and detecting, via the forecasting model, outputs that indicate a high likelihood of seizure. The intracranial implant and associated method may further apply via the brain-contacting electrodes, a prophylactic treatment to the brain to prevent a seizure from occurring, based on detecting an output indicating a high likelihood of seizure.
Owner:KINGS COLLEGE LONDON

Mycobacterium tuberculosis tandem DNA vaccine W543 as well as preparation method and application thereof

The invention discloses a mycobacterium tuberculosis tandem DNA vaccine W543 as well as a preparation method and application thereof. The DNA vaccine W543 provided by the invention is a novel mycobacterium tuberculosis DNA vaccine with multiple antigen immunodominance epitopes, which is constructed by connecting polypeptides or epitope coding genes of a mycobacterium tuberculosis proliferation period antigen and a latent related antigen in series through a linker by virtue of genetic engineering and inserting the polypeptides or epitope coding genes into an eukaryotic expression vector pVAX1. Experiments prove that the mycobacterium tuberculosis specific tandem DNA vaccine W543 disclosed by the invention is used as an immunomodulatory preparation, mainly stimulates immune response of Th1 type, and can significantly enhance the specific cellular immune function of mice; as a preventive treatment preparation, the bacterial count of lung and liver tissues can be reduced, the lesion range of the lung tissues is remarkably reduced, the lesion is relieved, and the treatment effect is slightly superior to that of an existing commercial tuberculosis latent infection prevention and treatment preparation, namely, microkalidium vaccine.
Owner:中国人民解放军总医院第八医学中心

Fatty acid derivatives for treating non-alcoholic steatohepatitis

The present disclosure provides a compound for use in therapeutic and / or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and / or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and / or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.
Owner:BASF AS

Olmesartan medoxomil single drug and application of olmesartan medoxomil and sorafenib combined therapy in prevention / treatment of diabetes mellitus

The invention provides an application of olmesartan medoxomil or a derivative thereof in preparation of a medicine for protecting pancreatic beta cells, a medicine for protecting pancreatic beta cells to resist inflammation, a medicine for preventing and treating diabetes mellitus and a medicine for preventing and treating type 1 diabetes mellitus, and also provides an application of olmesartan medoxomil or a derivative thereof in preparation of a medicine for preventing and treating type 1 diabetes mellitus. The invention also provides application of the olmesartan medoxomil and sorafenib combined therapy in treatment of type 1 diabetes mellitus. The olmesartan medoxomil is used for preventive treatment of the type 1 diabetes mellitus, and the olmesartan medoxomil and sorafenib combined therapy is used for treatment of the type 1 diabetes mellitus, so that a new treatment way is provided for the majority of patients, and more choices are provided for clinicians and the patients. For patients with type 1 diabetes, the preventive treatment of olmesartan medoxomil and the combination therapy of olmesartan medoxomil and sorafenib can provide oral drug therapy for the patients, and the trouble of CD3 monoclonal antibody injection even daily insulin injection is avoided.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Targeted gastrointestinal tract delivery of probiotic organisms and / or therapeutic agents

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and / or right colon of a human subject.
Owner:THERABIOME LLC

Timing and dosing improvements for diabetes management

In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.
Owner:DEXCOM INC

Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed -loop prophylactic treatment of hypoglycemia

PendingUS20250025411A1Peptide/protein ingredientsOxidoreductasesLow glucoseGlucagon preparation
Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under-utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.
Owner:MASSACHUSETTS INST OF TECH +1

Kilohertz e-tns stimulation

InactiveJP2024167443AExternal electrodesArtificial respirationTrigeminal nerve stimulationProphylactic treatment
To provide a device and a method for the abortive or preventive treatment of a headache via external trigeminal nerve stimulation, in particular, transcutaneous non-invasive electrical trigeminal stimulation via consecutive pulses.SOLUTION: Pulses 102 include: a pulse repetition frequency 123 of 0.5 kilohertz to 50 kilohertz; a pulse width 121 of 1 microsecond to 500 microseconds; and a pulse amplitude 111 of 0.1 milliampere to 200 milliamperes.SELECTED DRAWING: Figure 1
Owner:CEFALY TECH SPRL

IgY Antibody Compositions and Methods for Treating Mammal Species

A composition and method for therapeutic or prophylactic treatment of mammals includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum. In some embodiments the composition can also include IgA and IgM antibodies.
Owner:MAMMAL LABS LLC

Novel immunotherapy compositions and uses thereof

The present application relates to novel immunotherapeutic compositions and uses thereof. The present invention relates generally to an immunotherapeutic composition. More specifically, the present invention relates to an immunotherapeutic composition that immunointeracts with T lymphocytes in a subject suffering from peanut allergy or allergy to other tree nuts. Such compositions preferably react immunologically with T cells in a subject suffering from an allergy to an Ara h 1 and / or Ara h 2 allergen. The compositions of the present invention are useful in the therapeutic or prophylactic treatment of conditions characterized by an abnormal, improper or otherwise unwanted immune response to peanut, Ara h1 and / or Ara h2, or a derivative or homolog thereof.
Owner:ARAVAX

GSTO1 inhibitor and application thereof

The invention belongs to the field of chemical synthesis, and relates to a GSTO1 inhibitor and application thereof, and application of the compound in medicines for treating or prophylactically treating diseases related to GSTO1, in particular to a compound shown as a formula I, or an isomer thereof, or pharmaceutically acceptable salt thereof and application thereof, and substituent groups in the formula I are as defined in the specification.
Owner:NANJING CHOMIX BIOTECH CO LTD

Articles of manufacture and methods for treatment using adoptive cell therapy

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
Owner:JUNO THERAPEUTICS INC

Oleylphosphocholine in the treatment of leishmaniasis

PCT designated stageWO2026057797A1Organic active ingredientsAntiparasitic agentsLeishmaniasisPhosphorylcholine
The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.
Owner:OBLITA THERAPEUTICS

Substituted pyrrole-2,5-dione compounds and preparation methods and uses thereof

The present invention belongs to the field of medical technology, discloses substituted pyrrole-2,5-dione compounds and preparation methods and uses thereof, relates to pharmaceutical compositions in which the compounds are active ingredients, and their applications in treating and / or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound of the present invention, wherein R1, R2, and R3 are as described in the specification. The present invention aims to prepare a new compound having anti-mycobacterium tuberculosis activity, which, as a potential new drug, can be used for infectious diseases caused by bacteria, particularly for the treatment or preventive treatment of pulmonary tuberculosis (TB) diseases caused by Mycobacterium tuberculosis.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Diaminophenothiazines for treatment of microvascular brain diseases

The present invention provides a method of therapeutic or prophylactic treatment of microvascular brain disease in a subject comprising orally administering to the subject a reduced form of a compound comprising methylthionine (MT) wherein the administration provides the subject with 8 to 200 mg MT per day, optionally divided into two or more doses.
Owner:TAURX THERAPEUTICS MANAGEMENT LTD

A vaccine against leptospira bacterium

The invention pertains to a vaccine comprising a non-replicating Leptospira immunogen, for use in prophylactically treating a pig against an infection with a Leptospira bacterium, by injection of the first vaccine into the dermis of the pig.
Owner:INTERVET INT BV +1

Antigen-binding polypeptides against CD73

The invention relates to antigen-binding polypeptides comprising the CDR1, CDR2 and CDR3 region of a VHH domain of a camelid heavy chain antibody. The polypeptides bind specifically to CD73 and are therefore suitable for the diagnosis as well as for the therapeutic and prophylactic treatment of diseases characterised by increased CD73 expression. Conjugates and pharmaceutical compositions comprising the antigen-binding polypeptides are also disclosed. In addition, the invention relates to the use of such antigen-binding polypeptides in methods for detecting CD73 or CD73-expressing cells in a biological sample. Methods for purifying and concentrating CD73 or CD73-expressing cells using the antigen-binding polypeptides are also described.
Owner:UNIVERSITAETSKLINIKUM HAMBURG EPPENDORF

BCG vaccinations for prevention of covid-19 and other infectious diseases

The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.
Owner:THE GENERAL HOSPITAL CORP

Prophylactic skin treatment for radiation therapy

Methods of reducing skin fibrosis by prophylactically treating skin prior to radiation therapy are described herein. The methods include applying an effective amount of DFO to skin that may be subjected to radiation, e.g., during treatment for cancer at a treatment site. The DFO may be administered transdermally.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Method and apparatus for the treatment of migraine and other conditions

PCT designated stageWO2025222120A1Nervous disorderPneumatic massageWithin blood vesselsPhysical medicine and rehabilitation
Embodiments described herein generally relate to methods and apparatus for adjusting and / or controlling body temperature and / or the flow of blood within blood vessels within a mammal. Embodiments of the present disclosure may further provide a therapeutic method for acute and preventive treatment of a migraine headache or other recurrent acute or chronic pain of a user, comprising: applying a vacuum to a portion of a body of a user and circulating warmed water over a surface of the portion of the body of the user, wherein applying the vacuum and circulating the warmed water is configured to overcome a vasoconstricted state of the portion of the body and manipulate blood flow to a head and / or distal appendages of the user.
Owner:AVACORE TECH

Biomarker for predicting preventive response of gout patient to colchicine and application of biomarker

The invention discloses a group of biomarkers for predicting preventive response of gout patients to colchicine and application of the biomarkers, and relates to the technical field of biomedicine. The marker provided by the invention comprises Sm d42: 3, Cis-13-docosenic acid (erucic acid), Creatinine (creatinine), Gitoxin (hydroxydigitonin) and Trichosanic acid (tricosic acid). The invention also provides a kit and a detection system which are prepared by applying the marker and are used for predicting the preventive response of the gout patient to colchicine. Through the biomarker, the kit and the prediction system, whether the colchicine is effective in preventing gout attack can be accurately predicted, and more accurate preventive treatment is facilitated.
Owner:CHARLIE GAUTE (QINGDAO) HEALTH TECH CO LTD

Use of an immune checkpoint inhibitor in the manufacture of a medicament for prophylactic treatment of cancer in a subject

The application discloses application of an immune checkpoint inhibitor. One of the applications is the application in the preparation of a drug for preventing and treating cancer in a subject. The embodiments of the application show that the application of the immune checkpoint inhibitor to the early cancer stage (high-grade intraepithelial neoplasia stage (HGIN)) of esophageal squamous cell carcinoma can reverse the progression of esophageal squamous cell carcinoma lesions, effectively control the recurrence and metastasis of cancer.
Owner:BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY

Novel immunotherapeutic composition and uses thereof

The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and / or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and / or Ara h 2 or derivative or homologue thereof.
Owner:ARAVAX

DHP-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory damages of the visual pathway

PendingAU2024403005A1Blood-retina barrierDepressant
The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.
Owner:TELARA PHARMA SL +2

Compositions for use in the prophylactic treatment of hypocalcemia in a ruminant animal

PendingUS20260207659A1Phosphate TransportersCalcium Binder
Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.
Owner:VILOFOSS AS

Novel anti-HSV antibody

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.
Owner:HEIDELBERG IMMUNO THERAPEUTICS GMBH